Sandu Pharmaceuticals Stock Plummets to New 52-Week Low at Rs. 40.21
Sandu Pharmaceuticals has reached a new 52-week low, reflecting a notable decline in its stock price over the past year. The company has consistently underperformed against market benchmarks and exhibits weak long-term fundamentals, including low Return on Equity and challenges in servicing its debt obligations.
Sandu Pharmaceuticals has reached a new 52-week low, hitting Rs. 40.21 today, November 17, 2025. This marks a significant decline for the microcap company, which has seen its stock price decrease by 24.53% over the past year, contrasting sharply with the Sensex's performance of 9.20% during the same period.The stock has consistently underperformed against the benchmark, trailing the BSE500 for three consecutive years. Today, Sandu Pharmaceuticals underperformed its sector by 1.61%, and it is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent downward trend.
Financial metrics reveal weak long-term fundamentals, with an average Return on Equity (ROE) of just 3.73%. The company's net sales have grown at an annual rate of 4.69%, while operating profit has increased by 17.92% over the last five years. Additionally, Sandu Pharmaceuticals has a low EBIT to Interest ratio of 1.92, suggesting challenges in servicing its debt obligations.
As the market continues to evolve, Sandu Pharmaceuticals faces significant hurdles in regaining momentum.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
